TrialJAMA oncology2018

Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial.

Guy Jerusalem et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.